One of the more interesting moves that came this quarter was from the Duquesne Family Office, led by billionaire investor ...

As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline.  | As obesity ...

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...

Replicate Bioscience will partner with Novo Nordisk to develop treatments using self-replicating RNA technology for obesity, type 2 diabetes and other cardiometabolic diseases, the privately held ...

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk (NVO) will be forced to lower employee bonuses in its home country, Denmark, as the company doubles down on a ...

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.